TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28111929
Drug: Delayed-release omeprazole
Normalized name: omeprazole Delayed Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed-release omeprazole (omeprazole-DR, Losec 40 mg)
Study: 18289655
Drug: Physical Activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical Activity (PA) of varying doses (frequency, intensity, duration)
Study: 10892694
Drug: Pulsatile hypertonic
Normalized name: PULSATILLA PRATENSIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsatile hypertonic saline nasal irrigation using a Water Pik device, twice daily for 3 to 6 weeks.
Study: 9534937
Drug: LOW plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: LOW plasma volume expansion (14% using 6% dextran solution)
Study: 9534937
Drug: HIGH plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIGH plasma volume expansion (21% using 6% dextran solution)
Study: 7961010
Drug: Concurrent cis-platinum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent cis-platinum and radiation (20 mg/m2 continuous infusion over 24 hours on days 1-4 and 22-25 of radiation schedule)
Study: 7961010
Drug: Concurrent cis-platinum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent cis-platinum and radiation
Study: 31960896
Drug: Volux injectable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volux injectable gel
Study: 27404053
Drug: MPFF 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPFF 1000 mg
Study: 16052316
Drug: Ondansetron monotherapy
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron monotherapy
Study: 10642806
Drug: Budesonide 9
Normalized name: budesonide 9 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 9 mg/day divided into three doses
Study: 9032894
Drug: 0.1 ml
Normalized name: ethanol 0.1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 ml (2 micrograms) of recombinant hepatitis B vaccine
Study: 9032894
Drug: 1.0 ml
Normalized name: digoxin 0.25 mg in 1.0 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 ml (20 micrograms) of recombinant hepatitis B vaccine
Study: 1296148
Drug: carbocalcitonin nasal
Normalized name: Procalcitonin
DrugBank: Procalcitonin (DB14812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: carbocalcitonin nasal spray 80 UMRC/day/1 month and 80 UMRC/alternating days/2 months followed by 1 month of wash-out for 11 months
Study: 1296148
Drug: ipriflavone x
Normalized name: IPRIFLAVONE
DrugBank: Ipriflavone (DB13618)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ipriflavone x os 600 mg/day/3 months followed by 1 month of wash-out for 3 times
Study: 26654691
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as Usual (Phase 1)
Study: 24611967
Drug: Metformin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (250 mg t.i.d.) and carnitine-orotate complex (300 mg t.i.d.)
Study: 24611967
Drug: Metformin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (250 mg t.i.d.)
Study: 20001318
Drug: Active LLLT
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active LLLT with nimesulide 200 mg/day
Study: 20001318
Drug: Placebo LLLT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo LLLT with nimesulide 200 mg/day
Study: 2354092
Drug: Morphine sulphate
Normalized name: Morphine sulphate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine sulphate 500 micrograms
Study: 2354092
Drug: Morphine-6-glucuronide (M6G)
Normalized name: MENTHOL GLUCURONIDE
DrugBank: Morphine glucuronide (DB06409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine-6-glucuronide (M6G) 500 micrograms
Study: 2354092
Drug: Morphine sulphate
Normalized name: Morphine sulphate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine sulphate
Study: 25744158
Drug: Erythritol 20
Normalized name: pentaerythritol 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythritol 20 g
Study: 25744158
Drug: Erythritol 25
Normalized name: Erythritol
DrugBank: Erythritol (DB04481)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythritol 25 g
Study: 25744158
Drug: Erythritol 15
Normalized name: Erythritol
DrugBank: Erythritol (DB04481)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythritol 15 g
Study: 25744158
Drug: Erythritol 5
Normalized name: pentaerythritol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythritol 5 g
Study: 21370769
Drug: Additional manual
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional manual therapy techniques to the temporomandibular region
Study: 21370769
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care group (manual therapy for the cervical region)
Study: 19227169
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural infusion (ropivacaine 0.18% and fentanyl 45.5 microg x ml(‐1) at 2 ml x hr(‐1))
Study: 19227169
Drug: Continuous hypodermic
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous hypodermic infusion (morphine 0.04 mg x kg(‐1) x ml(‐1) at 0.5 ml x hr(‐1); bolus: 0.5 ml x hr(‐1))
Study: 10868317
Drug: Warfarin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin and Celecoxib
Study: 29222135
Drug: Ambulatory treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambulatory treatment (OP)
Study: 24694475
Drug: Steroids alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids alone (methylprednisolone, MP group; n=25)
Study: 24694475
Drug: Steroids plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids plus cyclosporine A (combination group; n=23)
Study: 21600712
Drug: Gauze packing
Normalized name: Nu-Gauze Packing Strip Selvage Edge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gauze packing (Group G)
Study: 8786250
Drug: PABA 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PABA 1.5 g orally every 6 hours for 5 days with intravenous procainamide 750 mg
Study: 8786250
Drug: Intravenous procainamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous procainamide alone
Study: 37493
Drug: Ketotifen (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen (2 x 1 mg)
Study: 37493
Drug: Ketotifen (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen (2 x 2 mg)
Study: 37493
Drug: Clemastine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clemastine (2 x 1 mg)
Study: 37493
Drug: Ketotifen (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen (3 and 14 days after treatment)
Study: 28921654
Drug: Alcohol administration
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol administration (0.0 and 0.65 g/kg)
Study: 19028832
Drug: Cyclic methylprednisolone
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic methylprednisolone (MP) in combination with azathioprine (AZA) for 6 months
Study: 2189989
Drug: Naftifine cream
Normalized name: naftifine Topical Cream
DrugBank: Naftifine (DB00735)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naftifine cream 1%
Study: 7000475
Drug: Cimetidine (1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (1.6 g/day)
Study: 31405646
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (100 μg or 4000 IU daily)
Study: 7537170
Drug: Astemizole-D (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astemizole-D (10 mg astemizole plus 240 mg pseudoephedrine) once daily
Study: 7537170
Drug: Beclomethasone nasal
Normalized name: beclomethasone nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone nasal spray (0.05 mg/ml) two puffs/nostril twice daily
Study: 31913907
Drug: Stereotactic body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic body radiation therapy (SBRT) for stage I NSCLC
Study: 19761652
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (10 mg Zn2+/day)
Study: 16720138
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g cefazolin (group A)
Study: 16720138
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL isotonic sodium chloride solution (group B; control)
Study: 11760033
Drug: 0.1% dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% dexamethasone phosphate eye gel
Study: 15627154
Drug: 1% prednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% prednisolone acetate eye suspension
Study: 9159563
Drug: Frusemide administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide administered as a slow-rate infusion
Study: 9159563
Drug: Frusemide administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide administered in combination with 2 g of probenecid
Study: 9159563
Drug: Frusemide bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide bolus dose
Study: 3683453
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of mixed gangliosides (Cronassial)
Study: 31838596
Drug: Probiotic milk
Normalized name: PROBIOTIC
DrugBank: Bifidobacterium longum (DB19248)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic milk (Lactobacillus paracasei SD1) daily (group II)
Study: 28034704
Drug: Oral antioxidants
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antioxidants (2 g ascorbate, 1.2 g N-acetylcysteine, 600 mg lipoic acid, 30 mg beta carotene)
Study: 25421868
Drug: Evening dosing
Normalized name: Evening Dosing 24 HR Jornay 60 MG Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evening dosing of naftopidil
Study: 25421868
Drug: Morning dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning dosing of naftopidil
Study: 24024769
Drug: Chromium nicotinate
Normalized name: Chromium Nicotinate
DrugBank: Chromium nicotinate (DB14529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chromium nicotinate 50 μg (NC50)
Study: 24024769
Drug: Chromium nicotinate
Normalized name: Chromium Nicotinate
DrugBank: Chromium nicotinate (DB14529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chromium nicotinate 200 μg (NC200)
Study: 18321515
Drug: Psychological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological treatment before infertility treatment
Study: 14751919
Drug: Conservative treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatments for prostate cancer
Study: 11397883
Drug: Estring treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estring treatment (7.5 microg per 24 h)
Study: 8503751
Drug: Early, intensive,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early, intensive, gait‐focused physical therapy
Study: 8503751
Drug: Early, intensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early, intensive and conventional therapy
Study: 8503751
Drug: Routine conventional
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine conventional therapy that started later and was not intense
Study: 29136228
Drug: Opioid prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid prescription
Study: 28750549
Drug: Error augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Error augmentation
Study: 20833862
Drug: Multidisciplinary falls
Normalized name: Halls
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary falls prevention programme (including physiotherapy, occupational therapy, nurse, medical review, referral to specialists)
Study: 12760507
Drug: Mechanical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical treatment only (scaling and root planing)
Study: 11689389
Drug: Paricalcitol dosing
Normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paricalcitol dosing based on baseline intact parathyroid hormone (iPTH; PTH/80) level
Study: 11689389
Drug: Paricalcitol dosing
Normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paricalcitol dosing based on patient body weight (0.04 microgram/kg)
Study: 9393221
Drug: Antiretroviral combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral combination therapies (1991-1996)
Study: 8180867
Drug: 100% of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100% of 150 ml of nonionic contrast agent (ivoversol, 320 mg/ml)
Study: 8180867
Drug: 75% of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75% of 150 ml of nonionic contrast agent (ivoversol, 320 mg/ml)
Study: 8180867
Drug: 65% of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 65% of 150 ml of nonionic contrast agent (ivoversol, 320 mg/ml)
Study: 8180867
Drug: 50% of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% of 150 ml of nonionic contrast agent (ivoversol, 320 mg/ml)
Study: 8180867
Drug: 30% of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30% of 150 ml of nonionic contrast agent (ivoversol, 320 mg/ml)
Study: 3286517
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg b.i.d. for UTI (22 cases)
Study: 3286517
Drug: Ciprofloxacin 250
Normalized name: ciprofloxacin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 250 mg b.i.d. for UTI (20 cases)
Study: 3286517
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg s.i.d. for UTI (20 cases)
Study: 3286517
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg b.i.d. for RTI (10 cases)
Study: 3286517
Drug: Ciprofloxacin 250
Normalized name: ciprofloxacin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 250 mg b.i.d. for RTI (20 cases)
Study: 24418877
Drug: 40 g
Normalized name: PEG-40 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g daily whole bean soy consumption for 18 months
Study: 14768515
Drug: Fentanyl-isoflurane anesthesia
Normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fentanyl-isoflurane anesthesia (infusion of fentanyl at 3 micrograms/kg/h and maintained with isoflurane up to 0.6% end-tidal concentration)
Study: 8676624
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg riluzole daily
Study: 8676624
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg riluzole daily
Study: 8676624
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg riluzole daily
Study: 30770426
Drug: Bright light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright light therapy (BLT) (±10,000 lux)
Study: 28474556
Drug: Ferritin levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferritin levels up to about 80 ng/mL
Study: 28474556
Drug: Ferritin levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferritin levels up to about 100 ng/mL
Study: 28474556
Drug: Ferritin levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferritin levels over 100 ng/mL
Study: 28474556
Drug: Modified normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified normal ranges for ferritin from about 15 ng/mL up to about 80-100 ng/mL
Study: 23614539
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TXA) - 1.0 g loading dose followed by another 1.0 g dose 3 hours later
Study: 21904221
Drug: Acute normovolemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute normovolemic hemodilution (HG) - 1000 mL of blood drawn and replaced with HES 130/0.4 (6%, Voluven) colloid.
Study: 18372722
Drug: Scopolamine (SCOP)
DrugBank: Scopolamine (DB00747)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Scopolamine (SCOP) in combination with dextroamphetamine (DEX)
Study: 9138853
Drug: Nadolol (hydrophilic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol (hydrophilic beta-blocker)
Study: 9138853
Drug: Metoprolol (lipophilic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (lipophilic beta-blocker)
Study: 7831697
Drug: Department of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Department of Medicine
Study: 2194380
Drug: Monovalent CR
Normalized name: rotavirus, monovalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent CR influenza virus vaccine (type A H3N2, H1N1 and type B)
Study: 2194380
Drug: Bivalent CR
Normalized name: L1 protein, human papillomavirus type 16 vaccine
DrugBank: Human papillomavirus type 16 L1 capsid protein antigen (DB10301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent CR influenza virus vaccine (type A H3N2 and H1N1)
Study: 2194380
Drug: CR influenza
Normalized name: INFLUENZA
Approvals — FDA: no, EMA: no, PMDA: no
Description: CR influenza virus vaccine
Study: 382156
Drug: Intravenous domperidone
Normalized name: Domperidone
DrugBank: Domperidone (DB01184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous domperidone (20 mg initially, followed by maintenance doses of 10 mg at 6 hourly intervals)
Study: 31475465
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil solution applied every 12 hours for 30 days
Study: 31475465
Drug: Hyperoxygenated fatty
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperoxygenated fatty acid compound applied every 12 hours for 30 days
Study: 29254111
Drug: FES therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: FES therapy plus conventional rehabilitation program
Study: 23392087
Drug: Oral hygiene
Normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hygiene instructions (OHI) annually (Control group)
Study: 23392087
Drug: OHI and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: OHI and SDF application annually, plus oral health education (OHE) programme every 6 months
Study: 15101070
Drug: Crisis intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crisis intervention model (additional therapy visits if needed)
Study: 15101070
Drug: Follow-up only
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follow-up only (no additional therapy visits)
Study: 3553495
Drug: Beta-blocker (oxprenolol)
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker (oxprenolol)
Study: 3553495
Drug: Calcium-entry blocker
Normalized name: CALCIUM CHANNEL BLOCKERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium-entry blocker (nitrendipine)
Study: 23414298
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of calcipotriol ointment twice daily (group I)
Study: 23414298
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of calcipotriol ointment twice daily and NB‐UVB phototherapy once a week (group II)
Study: 23414298
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of heparinoid ointment twice daily and NB‐UVB phototherapy more than twice a week (group III)
Study: 23414298
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of calcipotriol ointment twice daily and NB‐UVB phototherapy more than twice a week (group IV)
Study: 21347647
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus Tamoxifen (CTT)
Study: 17015900
Drug: Contrast-enhanced full-dose
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast-enhanced full-dose PET/CT
Study: 17015900
Drug: Unenhanced low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Unenhanced low-dose PET/CT
Study: 12643320
Drug: Danaparoid (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danaparoid (10 IU/kg) administered subcutaneously twice daily for a mean of 16 days.
Study: 12643320
Drug: Danaparoid (2.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danaparoid (2.6 IU/kg/h) administered intravenously for a mean of 17 days.
Study: 30362518
Drug: Chemoradiotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiotherapy plus enoxaparin (40 mg daily)
Study: 28619985
Drug: Rhythm-and-music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhythm-and-music therapy
Study: 28619985
Drug: Horse-riding therapy
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Horse-riding therapy
Study: 28619985
Drug: Rhythm-and-music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhythm-and-music therapy and Horse-riding therapy
Study: 19531521
Drug: Betamethasone (BM)
Normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone (BM) 12 mg
Study: 17915499
Drug: Classroom-administered cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classroom-administered cognitive enhancement program (COGENT) throughout the school year
Study: 15518095
Drug: Ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 4 mg with dexamethasone 8 mg (group OD)
Study: 3234635
Drug: Acetazolamide 250
Normalized name: acetazolamide 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide 250 mg three times daily for 3 days
Study: 31496659
Drug: Tiopronin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiopronin (15 mg/kg, 24 hrs)
Study: 31496659
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (792 mg/kg, 24 hrs)
Study: 28575389
Drug: Imipenem/cilastatin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem/cilastatin + 250 mg relebactam
Study: 28575389
Drug: Imipenem/cilastatin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem/cilastatin + 125 mg relebactam
Study: 28575389
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (treatment-emergent adverse events)
Study: 21968856
Drug: Dietetic Intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietetic Intervention Treatment (DIT)
Study: 19489504
Drug: G 6805
Approvals — FDA: no, EMA: no, PMDA: no
Description: G 6805 electronic stimulator
Study: 17406651
Drug: Measurement-based care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measurement-based care (MBC) approach with citalopram as the first treatment step